Innovation Pharmaceuticals Inc (IPIX)

[To infinity and beyond!]

I will say again that there is much to like about the data from the Gm- poster.

I suppose it is all about expectations. I will admit that my hopes were very high, maybe too high, for this presentation. I was hoping for the gm- equivalent of Brilacidin, and no such drug was unveiled. B has such blockbuster potential, and I say this as a shareholder and a clinician.

I do not think one drug has to rule them all-CRE , Acinetobacter, Pseudomonas, etc. I do not think that is reasonable, and that was never my expectation.

As a shareholder I want a drug that would be front line, big sales. Having a CRE drug is wonderful but those infections are rare and the value of such a drug is less than the value of a drug that covers Pseudomonas, if you had to pick